Total Funding
57
41
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
150360
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Acquired by 
Supernus Pharmaceuticals
Mary Jean Stempien: VP, Clinical ResearchPast Role: Syntex Corporation, Director, Medical Research- David Chernoff: Chief Medical OfficerPast Role: CardioDx, Chief Medical Officer
About the Company
Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The
company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.
